Ki-67 regulates global gene expression and promotes sequential stages of carcinogenesis
Karim Mrouj, Nuria Andrés-Sánchez, Geronimo Dubra, Priyanka Singh, Michal Sobecki, Dhanvantri Chahar, Emile Alghoul, Ana Bella Aznar, Susana Prieto, Nelly Pirot, Florence Bernex, Benoît Bordignon, Cédric Hassen‐Khodja, Martín Villalba, Liliana Krasińska, Daniel Fisher
Abstract
Ki-67 is a nuclear protein that is expressed in all proliferating vertebrate cells. Here, we demonstrate that, although Ki-67 is not required for cell proliferation, its genetic ablation inhibits each step of tumor initiation, growth, and metastasis. Mice lacking Ki-67 are resistant to chemical or genetic induction of intestinal tumorigenesis. In established cancer cells, Ki-67 knockout causes global transcriptome remodeling that alters the epithelial-mesenchymal balance and suppresses stem cell characteristics. When grafted into mice, tumor growth is slowed, and metastasis is abrogated, despite normal cell proliferation rates. Yet, Ki-67 loss also down-regulates major histocompatibility complex class I antigen presentation and, in the 4T1 syngeneic model of mammary carcinoma, leads to an immune-suppressive environment that prevents the early phase of tumor regression. Finally, genes involved in xenobiotic metabolism are down-regulated, and cells are sensitized to various drug classes. Our results suggest that Ki-67 enables transcriptional programs required for cellular adaptation to the environment. This facilitates multiple steps of carcinogenesis and drug resistance, yet may render cancer cells more susceptible to antitumor immune responses.